Thinness obsession prompts diet drug misuse in South Korea
SEOUL (The Korea Herald/ANN): A wave of demand for weight-loss medication is sweeping South Korea, a country that…
Wegovy won’t be in Canadian public drug plans as Novo Nordisk refuses talks – National
Negotiations that could have led to coverage of weight-loss drug Wegovy under Canadian public health plans are not…
Will blockbuster obesity drugs revolutionize addiction treatment?
Last April, neuroscientist Sue Grigson received an e-mail from a man detailing his years-long struggle to kick addiction…
Food expert Marion Nestle on calories, corruption, and shredded wheat
Marion Nestle doesn’t understand why people are so obsessed with her diet. Yes, she’s one of the world’s…
Fat sensory cues in early life program central response to food and obesity
Animal care Animal care, handling, and experimental procedures were conducted in compliance with protocols approved by local government…
Lilly cuts price for obesity drug Zepbound
Trump announces lower prices coming for GLP-1 drugs Zepbound, Wegovy President Donald Trump announces discounted pricing for Zepbound…
Early-life nutrition | National Institutes of Health (NIH)
Research in Context  November 25, 2025 Exposures in the womb can affect lifelong health Nutrition matters, and what young,…
Ozempic-style drugs should be available to all, not just the rich, says WHO – POLITICO
The WHO wants pharma companies to consider tiered pricing (lower prices in lower-income countries) and voluntary licensing of…
Simple food swaps can lower risk of chronic diseases, doctor says
NEWYou can now listen to Fox News articles! Nutrition can be the key to warding off disease —…
U.K. expanding its sugar tax to include milk-based drinks
London — In British supermarkets these days, there’s a war being waged against sugar, with the U.K. this week…
Alternate-day fasting cuts body fat but also reduces muscle
Nov 28 2025 New research shows that while four weeks of alternate-day fasting can quickly reduce body weight…
Dulaglutide, semaglutide, and tirzepatide exhibit comparable gastrointestinal adverse event risk
1. In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in…